IMGN News and Press, ImmunoGen Inc. From 05/03/19

ImmunoGen (NASDAQ: IMGN ): Q1 GAAP EPS of -$0.30 beats by $0.03 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy FORWARD II Trial with Mirvetuximab Combinations Continues to Enr...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Read more ...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter operating results. Management wi...

Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...

Roche ( RHHBY ) announced that it had received European approval for MabThera to treat patients with pemphigus vulgaris ((PV)). This approval is a good one, because it will help expand the market opportunity for MabThera. Especially, since the company had already received approval for th...

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Evoke Pharma Tumbles After Preliminary NDA Review News: Recently, Evoke Pharma ( EVOK ) tumbled by 51% on the announcement that the FDA was not sat...

CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The ascendancy of the biotech stock market to where it is today has only been made possible by the fact that biotech companies continue to formulate and manufacture top-of-the-line technologies for the purpose of the betterment of the human e...

Invitae (NYSE: NVTA ) initiated with Buy rating and $29 (43% upside) price target at Chardan Capital Markets. Shares up  2%  premarket. More news on: Invitae, ImmunoGen, Inc., Zoetis, Stocks on the move, Healthcare stocks news, Read more ...